What is the etiological relationship between ankylosing spondylitis and psoriasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Etiological Relationship Between Ankylosing Spondylitis and Psoriasis

Ankylosing spondylitis (AS) and psoriasis are distinct but genetically overlapping diseases that share common inflammatory pathways and susceptibility genes, most notably HLA-B27, though they represent separate clinical entities rather than different manifestations of the same disease.

Shared Genetic Architecture

The genetic overlap between AS and psoriasis is substantial and well-documented. Both conditions share susceptibility genes including HLA-B27, IL-23R, ERN1, and IFIH1 1. Recent genetic studies demonstrate that genetically predicted AS has positive causal effects on psoriasis risk (OR = 1.009, p = 8.07E-07), though the reverse relationship—psoriasis causing AS—has not been established 2. This unidirectional genetic causality suggests AS may predispose to psoriatic manifestations through shared inflammatory mechanisms.

Additional shared genetic loci include:

  • PPP2R3C: Confers susceptibility to both psoriatic arthritis (PsA) and psoriasis vulgaris 1
  • IL-23R: Associated with axial PsA subtypes 1
  • KIF3A: Linked to psoriasis vulgaris 1

Clinical Overlap Through Psoriatic Arthritis

The connection between AS and psoriasis manifests most clearly through PsA, which serves as a clinical bridge between these conditions. Approximately 10% of AS patients have concurrent psoriasis 3, while 5% of PsA patients present with exclusively axial involvement resembling AS, and 20-50% have combined axial and peripheral disease 4.

Key Clinical Distinctions

Despite similarities, axial disease in PsA differs from AS in several critical ways 4:

Axial PsA characteristics:

  • Less symptomatic presentation
  • Asymmetric sacroiliitis (often asymptomatic)
  • "Skip" pattern of spinal involvement at any level
  • Rarely progresses to complete ankylosis
  • Preserved spinal mobility compared to AS
  • Presence of psoriatic plaques or nail changes (absent in pure AS)

AS characteristics:

  • More severe, symmetric disease
  • Progressive loss of spinal mobility
  • Higher likelihood of complete joint space loss
  • Absence of cutaneous psoriatic features

HLA-B27 as a Phenotypic Modifier

HLA-B27 status significantly influences the clinical presentation and appears to determine disease phenotype. HLA-B27-positive axial PsA shares clinical characteristics similar to AS with psoriasis, including greater structural damage (BASRI scores), while HLA-B27-negative axial PsA presents with less inflammatory pain and reduced structural damage 5. In AS patients with psoriasis, HLA-B27 positivity is independently associated with the diagnosis (OR 3.34) and lumbar structural damage (OR 2.14) 5.

Pathogenic Mechanisms

Shared Inflammatory Pathways

Both conditions involve dysregulation of similar cytokine networks:

  • TNF-α pathway: Both respond to TNF inhibitors 6, 7
  • IL-17 pathway: IL-17A inhibitors effective in both conditions 6, 7, 8
  • IL-23/IL-12 pathway: Shared susceptibility through IL-23R variants 1

Viral Hypothesis

Historical research suggested possible viral etiology, with elevated 2-5A levels (a viral replication indicator) found in both AS and PsA patients but not in rheumatoid arthritis 9. However, this remains speculative and has not been substantiated by modern molecular studies.

Clinical Implications for Diagnosis

The presence of psoriatic plaques or nail changes in a patient with axial disease definitively distinguishes axial PsA from AS 4. Conversely, patients displaying classic AS features without cutaneous manifestations should not receive a PsA diagnosis even if they later develop psoriasis.

Screening Recommendations

All patients with psoriasis should be screened for PsA at every visit, as 30-33% will develop arthritis, typically 10-11 years after skin disease onset 10. In the majority of cases (72.7%), skin lesions precede arthritis, though 14.9% develop joint symptoms first 10.

Treatment Convergence

The therapeutic overlap further supports shared pathogenic mechanisms. Both conditions respond to:

  • NSAIDs as first-line therapy 4, 11, 8
  • TNF inhibitors (monoclonal antibodies preferred for AS with uveitis or IBD) 6, 12, 7, 8
  • IL-17 inhibitors 6, 7, 8
  • JAK inhibitors 7, 8

Important caveat: IL-17 inhibitors may exacerbate inflammatory bowel disease and should be avoided in patients with known Crohn's disease 12.

Conclusion on Relationship

The etiological relationship is best characterized as genetic pleiotropy with shared inflammatory pathways rather than a single disease spectrum. The unidirectional genetic causality (AS→psoriasis but not psoriasis→AS), combined with distinct clinical phenotypes modified by HLA-B27 status, suggests these are separate diseases with overlapping genetic susceptibility and inflammatory mechanisms. The heterogeneity in axial PsA presentations—particularly the HLA-B27-negative phenotype—highlights the need for consensus definitions and further research into genetic drivers 5.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.